EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review

Muhammad Hamza Dawood, Muhammad Shahzeb Khan, Ahmed Mustafa Rashid, Wilhelm Haverkamp

Global Cardiology · 31.12.2025 · 3 (4)

DOI: 10.4081/cardio.2025.91 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Cardiology, online erschienen am 31.12.2025. Verfasst von Muhammad Hamza Dawood und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aldosterone plays a pivotal role in the progression of cardio-renal diseases by driving myocardial fibrosis, vascular dysfunction, and renal injury through both genomic and non-genomic mechanisms. While mineralocorticoid receptor antagonists have long served as the cornerstone of pharmacologic intervention, their use is limited by adverse effects such as hyperkalemia, gynecomastia, and incomplete suppression of aldosterone-mediated pathology. Aldosterone synthase inhibitors, a novel class of therapeutics, offer a promising alternative by targeting the enzymatic production of aldosterone at its source, thereby circumventing receptor-level limitations. This narrative review comprehensively explores the physiological role of aldosterone, critiques existing RAAS-targeted therapies, and provides an in-depth evaluation of the pharmacology, efficacy, and safety of emerging ASIs including baxdrostat, lorundrostat, and osilodrostat. Evidence from recent clinical trials such as BrigHTN, HALO, Target-HTN, and FIONE is synthesized to assess their clinical potential. In addition, the review highlights novel mechanistic frontiers including the role of ASIs in overcoming aldosterone escape, attenuating cardio-renal fibrosis, modulating neurohormonal dysregulation, and enabling precision therapy through pharmacogenomic stratification. Future directions emphasize drug design innovations such as adrenal-specific prodrugs and nanoparticle-based formulations. Overall, ASIs represent a mechanistically robust and clinically promising advancement in the treatment of heart failure, chronic kidney disease, and primary aldosteronism. Their integration into multidrug regimens and personalized treatment frameworks may redefine the therapeutic landscape of cardio-renal-metabolic disease.

Zitieren

APA

Dawood, M. H., Khan, M. S., Rashid, A. M., & Haverkamp, W. (2025). Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review. Global Cardiology, 3(4). https://doi.org/10.4081/cardio.2025.91

Vancouver

Dawood MH, Khan MS, Rashid AM, Haverkamp W. Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review. Global Cardiology. 2025;3(4). doi:10.4081/cardio.2025.91

BibTeX
@article{Dawood2025,
  author = {Dawood, Muhammad Hamza and Khan, Muhammad Shahzeb and Rashid, Ahmed Mustafa and Haverkamp, Wilhelm},
  title = {Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review},
  journal = {Global Cardiology},
  year = {2025},
  volume = {3},
  number = {4},
  doi = {10.4081/cardio.2025.91}
}
Kostenlos starten →